Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Comparison of Contrast Enhanced Digital Breast Tomosynthesis and Magnetic Resonance Imaging in Patients with Known Breast Lesions

Trial Status: active

This clinical trial compares a contrast enhanced digital breast tomosynthesis (CE-DBT) imaging device against conventional magnetic resonance imaging (MRI) acquired as a part of a standard clinical workup in patients with known breast lesions. Breast cancer is the most common type of cancer among women. Early detection through comprehensive breast cancer screening is essential to eliminating cancer deaths. The breast tomosynthesis device takes multiple mammogram pictures to obtain additional 3-dimensional information about the breast. MRIs use radiofrequency waves and a strong magnetic field rather than x-rays to provide detailed pictures of internal organs and tissues. The technique is valuable for the diagnosis of many pathologic conditions, including cancer. Contrast agents, like iohexol, are substances administered during imaging procedures that allows delineation of internal structures. Contrast enhanced mammography has been proposed as a potential replacement to contrast enhanced MRI, due to its lower cost, wider availability, and shorter exam time. By comparing the radiologist confidence level in evaluating patients with known breast lesions using a CE-DBT imaging device against the MRI pictures taken as part of standard clinical workup, researchers may be able to determine the accuracy of CE-DBT in identifying breast lesions to potentially develop CE-DBT scanning approaches for the future.